During the Constellation Software sell-off, even bullish institutional investors sold their positions. The reason wasn't a change in fundamentals but rather pressure to follow short-term momentum and appease shareholders. This behavior, driven by career risk, creates opportunities for investors focused on long-term business value.

Fairfax India, trading around $18, has a realizable intrinsic value of $35-40+. This massive discount persists because its monopoly-like assets are carried at understated values, and its shareholder base lacks investors willing to pay a premium to its stated book value.

Contrary to popular belief, the underlying business fundamentals (sales, profits) of value and growth indexes have grown at nearly the same rate this century. The vast performance gap is not due to better business results but rather investors' willingness to pay increasingly higher multiples for growth stocks.

While a soft market slows premium growth, it also reduces the need for capital to back new business. This frees up significant cash flow for Fairfax to execute accretive buybacks and other capital returns, especially when the stock trades at a discount to its intrinsic value.

Public market investors systematically underestimate sustained high growth (e.g., 60%+), defaulting to models that assume rapid deceleration. This creates an opportunity for private investors with longer time horizons to more accurately value these companies.

Fairfax follows a clear capital allocation framework. They prioritize open market buybacks when the stock is below 1.5 times price-to-book. Above that multiple, they shift capital towards closing out their Total Return Swaps, providing a predictable approach for investors.

The book "The Fairfax Way" reveals the company's early success wasn't merely from acquiring insurers at low valuations. The critical, often overlooked element was the immense time, money, and work required to revamp and stabilize these acquired operations to an acceptable level, a key lesson for value investors.

Fairfax executed a brilliant capital allocation move by selling a 10% stake in its subsidiary, Odyssey, to pension funds for 1.7 times its book value. They then used the billion-dollar proceeds to buy back their own undervalued parent company stock, which was trading at a discount of 0.9x book value.

Fairfax maintains a balance sheet with roughly $75 billion in investments against $25 billion in equity. This leverage is primarily funded by low-cost insurance float and some debt, creating a powerful engine for returns that the speakers argue is a "better mousetrap than Berkshire."